Ruxolitinib Rescues Multiorgan Clinical Autoimmunity in Patients With APS-1

The study on ruxolitinib, a JAK inhibitor, in three patients with autoimmune polyendocrine syndrome type-1 (APS-1) over at least 30 months showed significant clinical improvements in multiple autoimmune conditions, including alopecia, nail dystrophy, and mucosal candidiasis, among others. Hair regrowth was noted after 3 months, with full resolution of alopecia after 12 months. The treatment was well-tolerated with no major adverse events, except for transient anemia in one patient. These results suggest that JAK inhibitors like ruxolitinib could be effective for APS-1, but larger studies are needed to confirm these findings and evaluate long-term safety.